Hyperhomocysteinemia - an additional risk factor of thrombosis in systemic lupus erythematosus and antiphospholipid syndrome

Objective. To assess homocystein (HC) level in systemic lupus erythematosus (SLE) with antiphospholipid syndrome (APS) and its relation to thrombosis development and blood lipide spectrum disturbances. Material and methods. 32 pts (12 male and 20 female) with mean age 36 12 years and mean disease du...

Full description

Bibliographic Details
Main Authors: I. E. Shirokova, T M Reshelnyak
Format: Article
Language:Russian
Published: IMA PRESS LLC 2003-08-01
Series:Научно-практическая ревматология
Subjects:
Online Access:https://rsp.mediar-press.net/rsp/article/view/1209
_version_ 1797863022587281408
author I. E. Shirokova
T M Reshelnyak
author_facet I. E. Shirokova
T M Reshelnyak
author_sort I. E. Shirokova
collection DOAJ
description Objective. To assess homocystein (HC) level in systemic lupus erythematosus (SLE) with antiphospholipid syndrome (APS) and its relation to thrombosis development and blood lipide spectrum disturbances. Material and methods. 32 pts (12 male and 20 female) with mean age 36 12 years and mean disease duration 13 11 years were included. 8 pts had SLE without APS, 13 - SLE with APS and 11 - primary APS (PAPS). All pts were divided into 2 groups depending on blood HC level. 26 pts with HC level more than 12 mcg/d! were included In group 1 and 6 pts with HC level less than 12 mcg/dl - in group 2. HC level was measured with high efficacious liquid chromatography (HELC). Lipid-protein blood spectrum was assessed in all pts. Results. Elevated HC level was revealed in 26 from 32 pts: in 16 with SLE (including 12 pts with APS) and in 10 with PAPS. HC concentration did not depend on APS presence, but frequence of hyperhomocysteinemia (HHC) significantly associated with APS and thrombotic complications. 20 from 26 (76,9%) pts with HHC had thrombosis history. Only I from 6 (16,7%) pts with normal HC level had thrombosis history (exact Fisher test p=0,02). HC level did not depend on age and sex. Changes of blood lipid-protein indices were revealed in most pts. Lipid spectrum disturbances were confined largely to cholesterol elevation due to increase of atherogenic lipoproteins cholesterol. Only 22% of pts showed decrease of antiatherogenic lipoproteins concentration. Bblood lipid-protein spectrum indices did not depend on HC level. Conclusion. HHC is present in 84,6% of pts with APS (primary and secondary). In pts with APS HHC is more frequent than in pts without APS. HHC is associated with thrombotic complications. HHC and lipid-protein spectrum disturbances are independent risk factors of thrombotic complications in pts with SLE and APS.
first_indexed 2024-04-09T22:28:53Z
format Article
id doaj.art-d291f127a6254e549689479f1c46c113
institution Directory Open Access Journal
issn 1995-4484
1995-4492
language Russian
last_indexed 2024-04-09T22:28:53Z
publishDate 2003-08-01
publisher IMA PRESS LLC
record_format Article
series Научно-практическая ревматология
spelling doaj.art-d291f127a6254e549689479f1c46c1132023-03-22T13:45:39ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922003-08-01414394310.14412/1995-4484-2003-13311149Hyperhomocysteinemia - an additional risk factor of thrombosis in systemic lupus erythematosus and antiphospholipid syndromeI. E. ShirokovaT M ReshelnyakObjective. To assess homocystein (HC) level in systemic lupus erythematosus (SLE) with antiphospholipid syndrome (APS) and its relation to thrombosis development and blood lipide spectrum disturbances. Material and methods. 32 pts (12 male and 20 female) with mean age 36 12 years and mean disease duration 13 11 years were included. 8 pts had SLE without APS, 13 - SLE with APS and 11 - primary APS (PAPS). All pts were divided into 2 groups depending on blood HC level. 26 pts with HC level more than 12 mcg/d! were included In group 1 and 6 pts with HC level less than 12 mcg/dl - in group 2. HC level was measured with high efficacious liquid chromatography (HELC). Lipid-protein blood spectrum was assessed in all pts. Results. Elevated HC level was revealed in 26 from 32 pts: in 16 with SLE (including 12 pts with APS) and in 10 with PAPS. HC concentration did not depend on APS presence, but frequence of hyperhomocysteinemia (HHC) significantly associated with APS and thrombotic complications. 20 from 26 (76,9%) pts with HHC had thrombosis history. Only I from 6 (16,7%) pts with normal HC level had thrombosis history (exact Fisher test p=0,02). HC level did not depend on age and sex. Changes of blood lipid-protein indices were revealed in most pts. Lipid spectrum disturbances were confined largely to cholesterol elevation due to increase of atherogenic lipoproteins cholesterol. Only 22% of pts showed decrease of antiatherogenic lipoproteins concentration. Bblood lipid-protein spectrum indices did not depend on HC level. Conclusion. HHC is present in 84,6% of pts with APS (primary and secondary). In pts with APS HHC is more frequent than in pts without APS. HHC is associated with thrombotic complications. HHC and lipid-protein spectrum disturbances are independent risk factors of thrombotic complications in pts with SLE and APS.https://rsp.mediar-press.net/rsp/article/view/1209antiphospholipid syndromesystemic lupus erythematosushomocystein
spellingShingle I. E. Shirokova
T M Reshelnyak
Hyperhomocysteinemia - an additional risk factor of thrombosis in systemic lupus erythematosus and antiphospholipid syndrome
Научно-практическая ревматология
antiphospholipid syndrome
systemic lupus erythematosus
homocystein
title Hyperhomocysteinemia - an additional risk factor of thrombosis in systemic lupus erythematosus and antiphospholipid syndrome
title_full Hyperhomocysteinemia - an additional risk factor of thrombosis in systemic lupus erythematosus and antiphospholipid syndrome
title_fullStr Hyperhomocysteinemia - an additional risk factor of thrombosis in systemic lupus erythematosus and antiphospholipid syndrome
title_full_unstemmed Hyperhomocysteinemia - an additional risk factor of thrombosis in systemic lupus erythematosus and antiphospholipid syndrome
title_short Hyperhomocysteinemia - an additional risk factor of thrombosis in systemic lupus erythematosus and antiphospholipid syndrome
title_sort hyperhomocysteinemia an additional risk factor of thrombosis in systemic lupus erythematosus and antiphospholipid syndrome
topic antiphospholipid syndrome
systemic lupus erythematosus
homocystein
url https://rsp.mediar-press.net/rsp/article/view/1209
work_keys_str_mv AT ieshirokova hyperhomocysteinemiaanadditionalriskfactorofthrombosisinsystemiclupuserythematosusandantiphospholipidsyndrome
AT tmreshelnyak hyperhomocysteinemiaanadditionalriskfactorofthrombosisinsystemiclupuserythematosusandantiphospholipidsyndrome